HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of adamantylamide dipeptide on reinfection resistance after primary infection eradication in experimental Schistosomiasis mansoni.

Abstract
The immunomodulatory effect of adamantylamide dipeptide (AdDP) was tested in Schistosoma mansoni-infected challenged mice and infected praziquantel-treated (2 x 500 mg/kg) challenged animals. In AdDP-treated mice, the drug was given 58 days post infection of mice with 120 S. mansoni cercariae, challenged with 240 cercariae one day after treatment, while in praziquantel-treated mice, the drug was given 44 days post infection, two weeks post treatment (58 days post infection) they were given AdDP in the same dose and one day later challenged with the same cercarial load. AdDP increased the resistance against reinfection (90.3% vs. 83.5% in infected challenged control). The significant increase in resistance against reinfection was accompanied by significant increase in the percentage of lymphocytes forming EAC rosettes. Mice cured of their primary infection by praziquantel showed a significant reduction in percent resistance, hepatic granuloma size and intragranulomal Thy+ 1,2 and Lyt+ 1 T cells. In mice treated with both praziquantel and AdDP, resistance to reinfection was significantly higher than in mice treated with praziquantel only (89.29% vs. 62.13%) reaching a level comparable to that recorded in infected-challenged controls. Meanwhile granuloma size was not significantly different from that in the infected-challenged controls with a significant rise in Lyt+ 1 T cells. Data may suggest a role for granuloma as a mechanical obstacle and/or as a T cell-mediated reaction in maintenance of resistance to reinfection. A role for B lymphocytes should be considered as the rise of percent resistance to reinfection in mice treated with AdDP alone was accompanied by a significant increase in the percentage of B lymphocytes forming EAC rosettes. Moreover, findings may suggest the use of AdDP together with specific chemotherapy in endemic areas where reinfection and repeated treatment with its consequences are of common occurrence.
AuthorsS Botros, S Mahmoud, S Hassan, A Ibrahim, Z Zidek, K Masek
JournalArzneimittel-Forschung (Arzneimittelforschung) Vol. 46 Issue 1 Pg. 74-8 (Jan 1996) ISSN: 0004-4172 [Print] Germany
PMID8821522 (Publication Type: Journal Article)
Chemical References
  • Adjuvants, Immunologic
  • Antiplatyhelmintic Agents
  • Dipeptides
  • Schistosomicides
  • Praziquantel
  • adamantylamide-alanyl-isoglutamine
  • Amantadine
Topics
  • Adjuvants, Immunologic (therapeutic use)
  • Amantadine (analogs & derivatives, therapeutic use)
  • Animals
  • Antibody Formation (drug effects)
  • Antiplatyhelmintic Agents (therapeutic use)
  • Dipeptides (therapeutic use)
  • Drug Resistance
  • Granuloma (parasitology)
  • Immunity, Cellular (drug effects)
  • Liver (parasitology)
  • Lymphocytes (parasitology)
  • Mice
  • Mice, Inbred Strains
  • Praziquantel (therapeutic use)
  • Rats
  • Recurrence
  • Schistosomiasis mansoni (drug therapy, immunology, parasitology)
  • Schistosomicides (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: